Close

Qualicaps to invest $26m for Whitsett facility expansion

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Indian Pharma Grows 8% CAGR, Surpassing Global Average

The Indian pharma sector has seen 8% CAGR growth...

New Syngene biologics manufacturing facility to be operational for US and European customers from mid-year

At DCAT 2024 global bio/pharmaceutical manufacturing forum, Syngene International,...

ST Pharm breaks ground on 2nd oligonucleotide manufacturing plant

ST Pharm said it has taken its first step...

Pharmaceutical manufacturer Qualicaps will invest $26m to expand its facility in Whitsett, North Carolina in the US.

Under the expansion plans, the firm will also add additional 100,000 ft² building space. The project will be funded by the Guilford County Board of Commissioners and the State of North Carolina, which are providing economic development incentive grants of $272,805 and $235,000 respectively.

Greensboro Economic Development Alliance president Dan Lynch said Qualicaps decision to expand their manufacturing operations validates the firm’s industry cluster strategy.

“Qualicaps represents two of our five clusters; life science and innovative manufacturing. By expanding in Guilford County they are able to benefit from our skilled workforce and leverage comprehensive training programs through GTCC,” Lynch added.

Qualicaps is a wholly owned subsidiary of Qualicaps Group, which is a manufacturer and supplier of two-piece medical and nutrition grade gelatin capsules.

 

Latest stories

Related stories

Indian Pharma Grows 8% CAGR, Surpassing Global Average

The Indian pharma sector has seen 8% CAGR growth...

New Syngene biologics manufacturing facility to be operational for US and European customers from mid-year

At DCAT 2024 global bio/pharmaceutical manufacturing forum, Syngene International,...

ST Pharm breaks ground on 2nd oligonucleotide manufacturing plant

ST Pharm said it has taken its first step...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back